This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Multiple Endocrine Neoplasia Market

Multiple Endocrine Neoplasia Market By Product Type (Proton Pump Inhibitors, Dopamine Agonist, Bromocriptine, Cabergoline, Antihypoglycemic Agents, Diazoxide, Octreotide, Calcimimetics), Distribution Channel (Hospitals, Specialty Clinics) & Region - Forecast 2022-2032

Market Insights on Multiple Endocrine Neoplasia covering sales outlook, demand forecast & up-to-date key trends

Multiple Endocrine Neoplasia Market Overview

The global multiple endocrine neoplasia market is projected to grow at a healthy CAGR of around 6.0% between 2022 and 2032. Increasing consumption of multiple endocrine neoplasia medicines to ease symptoms and improve quality of life is the main force driving the global multiple endocrine neoplasia market.

Report Attribute

Details

Multiple Endocrine Neoplasia Market Projected Growth Rate (2022-2032)

~6.0% CAGR

Multiple endocrine neoplasia (MEN) is a group of rare disorders that affects the endocrine system of a person’s body. These disorders are caused by genetic mutations and typically involve tumors in at least two endocrine glands. The MEN tumors can be either benign (noncancerous) or malignant (cancerous).

Presence of multiple endocrine neoplasia can result in the overproduction of hormones which in turn disturbs the proper functioning of body processes such as digestion, growth and reproduction. These tumors can cause various mild and severe symptoms and eventually degrade the quality of life of the affected person.

Multiple endocrine neoplasia has been classified into various types such as type 1 and type 2, depending on the affected gland. type 1 category involves tumors of parathyroid glands, pituitary gland and pancreas while as type 2 multiple endocrine neoplasia mostly affects thyroid and adrenal glands.

As multiple endocrine neoplasia disorders are triggered by genetic mutations, there is no proper treatment available for them right now. However, various drugs are being used to change or maintain the hormonal imbalance in the body. Besides this, tumors can also be surgically removed but that involves much higher risk to the affected individual.

Rising adoption of various advanced drugs such as proton pump inhibitors, dopamine agonist, bromocriptine, and cabergoline for reliving the symptoms and improving the quality of life will continue to boost the growth of multiple endocrine neoplasia market during the forecast period.

Which are Some Prominent Drivers Triggering the Growth of Multiple endocrine neoplasia Market Growth?

The robust expansion of multiple endocrine neoplasia market is attributed to the high prevalence of multiple endocrine neoplasia disorders, increasing research activities for the development of innovative drugs, growing health awareness among people, and rising governmental supports.

Increasing need for treating various types of multiple endocrine neoplasia is emerging as a key factor in driving the global multiple endocrine neoplasia market. These disorders badly affect the proper functioning of human body systems such as digestive system and reproduction system.

As there is no proper treatment available for MEN disorders, people are compelled to use drugs like proton pump inhibitors, dopamine agonist, bromocriptine etc. to relieve symptoms. Increasing consumption of these drugs will continue to boost the growth of multiple endocrine neoplasia market in the future.

Similarly, rising initiatives by government and private organizations for developing advanced treatment therapeutics for rare diseases is positively impacting the market growth. Various new researches are being conducted to explore the mechanism of multiple endocrine neoplasia. This will help the market players to develop more effective drugs in the future.

In addition to this, rapid expansion of healthcare infrastructures such as hospitals and specialty clinics will further accelerate the growth of multiple endocrine neoplasia market during the forecast period.

Customize this Report

Let us know your requirement to get
100% FREE customization

What are the Challenges Faced by the Multiple endocrine neoplasia Industry?

Despite its strong stance, there are various challenges that multiple endocrine neoplasia market is likely to face during the forecast period. Some of these factors are the high cost of treatment, lack of awareness among developing and underdeveloped regions, and various side effects associated with MEN drugs.

Patients who consume drugs like dopamine agonist, bromocriptine and cabergoline for relieving symptoms of multiple endocrine neoplasia disorders often face side effects such as postural hypotension, fatigue, nervousness, vision abnormalities, dizziness etc. This is becoming one of the major impediments for the growth of multiple endocrine neoplasia market.

What Makes North America the Most Dominant Market for Multiple Endocrine Neoplasia?

Spurred by increasing drug development activities, presence of well-established healthcare infrastructure and large base of leading market players, North America will continue to dominate the global multiple endocrine neoplasia market during the forecast period. 

Countries such as the United States are emerging as leading manufacturers of innovative drugs for treating rare disorders. These countries spend billions of dollars in medical research activities annually. This will continue to spur the growth of multiple endocrine neoplasia market across the region.

The United States is home to some of the leading pharmaceutical and biotechnological companies in the world. These companies are conducting various researches for developing effective treatments for rare diseases like MEN disorders.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How is Europe Contributing to Growth of the Multiple endocrine neoplasia Market?

According to Future Market Insights, Europe is expected to emerge as the second most lucrative market for multiple endocrine neoplasia during the forecast period, owing to the heavy presence of biotechnological giants, increasing investments in medical research activities and higher patient pool in countries like the United Kingdom and Germany.

During the last few years, there has been significant rise in the number of multiple endocrine neoplasia cases across the Europe. People are using various treatments options including drugs and surgeries to ease the symptoms and lead a quality life.

Moreover, various initiatives are being launched to educate people about rare diseases like multiple endocrine neoplasia, their diagnosis and treatment. This will continue to act as a catalyst for the growth of multiple endocrine neoplasia across the Europe.

Market Competition

Some of the key participants present in the global multiple endocrine neoplasia market include West Coast Pharmaceuticals, Unicure India Pvt. Ltd., Solvay Pharma India Pvt. Ltd., Sun Pharmaceuticals Industries Ltd., Macleods Pharmaceuticals Ltd., and Chemech Laboratories Ltd.

These key market players are constantly investing in research and development activities for introducing novel drugs that can effectively relieve the symptoms without adverse side effects. Besides this, they are adopting various growth strategies such as partnerships, acquisitions, collaboration and new product launches and approvals to expand their global presence.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Scope of Report 

Report Attribute

Details

Growth Rate

CAGR of 6.0% from 2022 t 2032

Base Year for Estimation

2021

Historical Data

2015-2020

Forecast Period

2022-2032

Quantitative Units

Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Product Type
  • Distribution Channel
  • Region

Regions Covered

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • Middle East and Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Argentina
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • ASEAN
  • GCC
  • South Africa

Key Companies Profiled

  • West Coast Pharmaceuticals
  • Unicure India Pvt. Ltd.
  • Solvay Pharma India Pvt. Ltd.
  • Sun Pharmaceuticals Industries Ltd.
  • Macleods Pharmaceuticals Ltd.
  • Chemech Laboratories Ltd

Customization

Available Upon Request

Key Segments Profiled in the Multiple Endocrine Neoplasia Industry Survey

By Product Type:

  • Proton Pump Inhibitors 
  • Dopamine Agonist  
  • Bromocriptine  
  • Cabergoline  
  • Antihypoglycemic Agents 
  • Diazoxide 
  • Octreotide
  • Calcimimetics 
  • Others

By Distribution Channel:

  • Hospitals 
  • Specialty Clinics
  • Others

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • Middle East & Africa

Frequently Asked Questions

As per FMI, the global multiple endocrine neoplasia market is projected to expand at a CAGR of around 6% between 2022 and 2032.

North America is forecast to remain the most lucrative market for multiple endocrine neoplasia market during the forecast period.

West Coast Pharmaceuticals, Unicure India Pvt. Ltd., Solvay Pharma India Pvt. Ltd., Sun Pharmaceuticals Industries Ltd. are some prominent multiple endocrine neoplasia manufacturers

Table of Content

NA

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

NA

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

NA

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Multiple Endocrine Neoplasia Market